Efficacy and safety of ICI-based triple combination therapy for gene-negative advanced lung adenocarcinoma

In order to evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) combined with anti-angiogenic agents and chemotherapy regimens as first-line treatment for gene-negative advanced lung adenocarcinoma, a retrospective analysis was performed on the clinical data of patients with driver gene-negative advanced lung adenocarcinoma who received the ICI-Based Triple Combination regimen at The Sixth Affiliated Hospital (School of Medicine, South China University of Technology, Foshan, China) between January 2022 and December 2024. Among the enrolled patients, the objective response rate was 58.3%, and the disease control rate was 83.3%. The median progression-free survival was 25.4 months [95% confidence interval (CI): 12.7-38.0 months], and the median overall survival was 26.6 months (95% CI: 21.3-31.8 months). The most common treatment-related adverse events were hematological toxicity (58.3%), followed by nausea and vomiting (50.0%), fatigue and anorexia (33.3%), muscle pain (33.3%) and chest tightness with shortness of breath (33.3%). All symptoms improved after symptomatic treatment. The present study showed that the ICI-based triple combination regimen exhibited promising antitumor activity and a manageable safety profile in patients with driver gene-negative advanced lung adenocarcinoma.